Deutsche Bank’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.46M | Sell |
162,682
-27,551
| -14% | -$1.27M | ﹤0.01% | 1066 |
|
|
2025
Q4 | $8.53M | Buy |
190,233
+77,282
| +68% | +$3.25M | ﹤0.01% | 1136 |
|
|
2025
Q3 | $4.53M | Buy |
112,951
+8,417
| +8% | +$296K | ﹤0.01% | 1353 |
|
|
2025
Q2 | $3.27M | Buy |
104,534
+50,823
| +95% | +$1.66M | ﹤0.01% | 1442 |
|
|
2025
Q1 | $1.8M | Hold |
53,711
| – | – | ﹤0.01% | 1824 |
|
|
2024
Q4 | $2.11M | Hold |
53,711
| – | – | ﹤0.01% | 1819 |
|
|
2024
Q3 | $2.11M | Hold |
53,711
| – | – | ﹤0.01% | 1707 |
|
|
2024
Q2 | $2.09M | Buy |
53,711
+15,000
| +39% | +$600K | ﹤0.01% | 1615 |
|
|
2024
Q1 | $1.67M | Buy |
38,711
+36,216
| +1,452% | +$1.67M | ﹤0.01% | 1758 |
|
|
2023
Q4 | $115K | Hold |
2,495
| – | – | ﹤0.01% | 3164 |
|
|
2023
Q3 | $85.2K | Sell |
2,495
-539
| -18% | -$20.2K | ﹤0.01% | 3232 |
|
|
2023
Q2 | $117K | Buy |
3,034
+539
| +22% | +$21.4K | ﹤0.01% | 3202 |
|
|
2023
Q1 | $89.3K | Hold |
2,495
| – | – | ﹤0.01% | 3379 |
|
|
2022
Q4 | $98.4K | Buy |
+2,495
| New | +$90.9K | ﹤0.01% | 3329 |
|
|
2021
Q4 | – | Sell |
-7,987
| Closed | -$122K | – | 4430 |
|
|
2021
Q3 | $122K | Buy |
7,987
+7,934
| +14,970% | +$138K | ﹤0.01% | 3818 |
|
|
2021
Q2 | $1K | Sell |
53
-35
| -40% | -$645 | ﹤0.01% | 4570 |
|
|
2021
Q1 | $2K | Sell |
88
-30,432
| -100% | -$516K | ﹤0.01% | 4509 |
|
|
2020
Q4 | $470K | Buy |
30,520
+51
| +0.2% | +$597 | ﹤0.01% | 2949 |
|
|
2020
Q3 | $337K | Hold |
30,469
| – | – | ﹤0.01% | 2887 |
|
|
2020
Q2 | $382K | Sell |
30,469
-64,611
| -68% | -$822K | ﹤0.01% | 2790 |
|
|
2020
Q1 | $1.08M | Buy |
95,080
+91,946
| +2,934% | +$1.31M | ﹤0.01% | 2052 |
|
|
2019
Q4 | $41K | Buy |
+3,134
| New | +$33K | ﹤0.01% | 4053 |
|
|
2019
Q3 | – | Sell |
-2,047
| Closed | -$19K | – | 5319 |
|
|
2019
Q2 | $19K | Sell |
2,047
-1,719
| -46% | -$16.4K | ﹤0.01% | 4831 |
|
|
2019
Q1 | $37K | Sell |
3,766
-69,434
| -95% | -$589K | ﹤0.01% | 4652 |
|
|
2018
Q4 | $461K | Buy |
73,200
+20,777
| +40% | +$185K | ﹤0.01% | 3393 |
|
|
2018
Q3 | $692K | Sell |
52,423
-68,800
| -57% | -$797K | ﹤0.01% | 3569 |
|
|
2018
Q2 | $1.11M | Buy |
+121,223
| New | +$753K | ﹤0.01% | 3350 |
|
|
2018
Q1 | – | Sell |
-8,719
| Closed | -$24K | – | 5625 |
|
|
2017
Q4 | $24K | Sell |
8,719
-100,840
| -92% | -$274K | ﹤0.01% | 4631 |
|
|
2017
Q3 | $323K | Buy |
109,559
+98,859
| +924% | +$306K | ﹤0.01% | 3630 |
|
|
2017
Q2 | $33K | Sell |
10,700
-2,037
| -16% | -$7.96K | ﹤0.01% | 4475 |
|
|
2017
Q1 | $50K | Sell |
12,737
-25
| -0.2% | -$197 | ﹤0.01% | 4222 |
|
|
2016
Q4 | $98K | Sell |
12,762
-15,986
| -56% | -$128K | ﹤0.01% | 4094 |
|
|
2016
Q3 | $232K | Buy |
28,748
+25,102
| +688% | +$194K | ﹤0.01% | 3573 |
|
|
2016
Q2 | $21K | Sell |
3,646
-3,970
| -52% | -$27.2K | ﹤0.01% | 4738 |
|
|
2016
Q1 | $53K | Sell |
7,616
-31
| -0.4% | -$223 | ﹤0.01% | 4297 |
|
|
2015
Q4 | $61K | Sell |
7,647
-4,238
| -36% | -$36.3K | ﹤0.01% | 4305 |
|
|
2015
Q3 | $98K | Sell |
11,885
-9,241
| -44% | -$91.8K | ﹤0.01% | 4121 |
|
|
2015
Q2 | $243K | Buy |
+21,126
| New | +$292K | ﹤0.01% | 3787 |
|
Other funds holding XENE
ACA
DCM
PCH
Deutsche Bank's XENE Position: Q1 2026 in Review
Deutsche Bank reduced its Xenon Pharmaceuticals (XENE) stake by 14% in Q1 2026, selling an estimated $1.27M and leaving 162,682 shares worth $9.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1066.
Deutsche Bank first reported a position in XENE in Q2 2015 and has held it in 38 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.
- Deutsche Bank held 162,682 shares of Xenon Pharmaceuticals worth $9.46M as of Q1 2026.
- Deutsche Bank sold 27,551 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.27M.
- Xenon Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1066 holding.
- Deutsche Bank first reported a position in Xenon Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.